Recently, Xiangsheng Medical officially announced its profit distribution plan for the first three quarters of 2023. According to the announcement, the company intends to distribute a cash dividend of RMB 2.5 per 10 shares (tax inclusive) to all shareholders, based on the total number of shares outstanding as of September 30, 2023. No bonus shares will be issued, and there will be no capitalization of reserves. The total dividend payout is estimated at approximately RMB 62.5 million, representing about 40% of the company’s net profit attributable to shareholders for the first nine months of the year.Xiangsheng Medical stated that this distribution plan takes into account the company’s current operational performance, future strategic development, and cash flow position, aiming to support sustainable growth while actively rewarding investors. In the first three quarters of 2023, the company reported an approximate 18% year-over-year increase in revenue and a 22% rise in net profit, driven primarily by continuous innovation in its ultrasound product line and successful expansion into international markets.Industry analysts note that Xiangsheng Medical has significantly increased R&D investment in high-end medical imaging in recent years, with its portable ultrasound devices gaining recognition in multiple emerging markets worldwide. This dividend plan reflects the company’s strong profitability and commitment to shareholder returns, potentially bolstering investor confidence further.
近日，祥生医疗（Xiangsheng Medical）正式公布了2023年前三季度利润分配方案。根据公告，公司拟以截至2023年9月30日的总股本为基数，向全体股东每10股派发现金红利人民币2.5元（含税），不送红股，也不进行资本公积金转增股本。此次分红总额预计约为6,250万元，占公司前三季度归属于上市公司股东净利润的约40%。祥生医疗表示，该利润分配方案充分考虑了公司当前经营状况、未来发展战略及现金流情况，在保障公司持续稳健发展的同时，积极回馈广大投资者。2023年前三季度，公司实现营业收入同比增长约18%，净利润同比增长约22%，主要得益于超声设备产品线的持续创新和国际市场拓展成效显著。业内人士指出，祥生医疗近年来在高端医学影像领域不断加大研发投入，其便携式超声设备已在全球多个新兴市场获得认可。此次分红方案体现了公司良好的盈利能力和对股东回报的重视，有望进一步增强投资者信心。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/3910.html